{"filing":{"accession_number":"0001104659-26-086760","cik":"0001697862","ticker":"ARGX","company_name":"ARGENX SE","form":"6-K","filing_date":"2026-07-27","report_date":"2026-07-27","primary_document":"tm2621326d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1697862/000110465926086760/tm2621326d1_6k.htm"},"events":[{"id":20575,"run_id":18519,"accession_number":"0001104659-26-086760","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"This is a definitive announcement of argenx's acquisition of Forte Biosciences for $77 per share in cash, representing approximately $2.2 billion in total equity value. The press release explicitly states that \"the companies have entered into a definitive agreement\" and describes the transaction structure (tender offer followed by merger), closing conditions, and expected timing (Q3 2026). This is a material acquisition that would significantly affect a reasonable investor's assessment of argenx's strategy, pipeline, and capital allocation.","company_name":"ARGENX SE","ticker":"ARGX","filing_date":"2026-07-27","form":"6-K","submitted_at":null,"items":[{"id":19979,"accession_number":"0001104659-26-086760","item_number":"EX-99.1","item_title":"tm2621326d1_ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"This is a definitive announcement of argenx's acquisition of Forte Biosciences for $77 per share in cash, representing approximately $2.2 billion in total equity value. The press release explicitly states that \"the companies have entered into a definitive agreement\" and describes the transaction structure (tender offer followed by merger), closing conditions, and expected timing (Q3 2026). This is a material acquisition that would significantly affect a reasonable investor's assessment of argenx's strategy, pipeline, and capital allocation.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-27T10:07:38.389530+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19979,"accession_number":"0001104659-26-086760","item_number":"EX-99.1","item_title":"tm2621326d1_ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"This is a definitive announcement of argenx's acquisition of Forte Biosciences for $77 per share in cash, representing approximately $2.2 billion in total equity value. The press release explicitly states that \"the companies have entered into a definitive agreement\" and describes the transaction structure (tender offer followed by merger), closing conditions, and expected timing (Q3 2026). This is a material acquisition that would significantly affect a reasonable investor's assessment of argenx's strategy, pipeline, and capital allocation.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-27T10:07:38.389530+00:00","company_name":"ARGENX SE","ticker":"ARGX","filing_date":"2026-07-27"}]}